OXYPERTINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H29N3O2.ClH
Molecular Weight	415.956
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.COC1=CC2=C(C=C1OC)C(CCN3CCN(CC3)C4=CC=CC=C4)=C(C)N2

InChI

InChIKey=USAPVNXIZYFWLO-UHFFFAOYSA-N

InChI=1S/C23H29N3O2.ClH/c1-17-19(20-15-22(27-2)23(28-3)16-21(20)24-17)9-10-25-11-13-26(14-12-25)18-7-5-4-6-8-18;/h4-8,15-16,24H,9-14H2,1-3H3;1H

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/5322447
Curator's Comment: Description was created based on several sources, including http://imr.sagepub.com/content/1/6/573.full.pdf

Oxypertine (Equipertine, Forit, Integrin, Lanturil, Lotawin, Opertil) is a neuroleptic drug and was originally introduced as a treatment for schizophrenia in the 1960s. Oxypertine is an indole derivative with general properties similar to those of the phenothiazine, chlorpromazine. It has been given by mouth in the treatment of various psychoses including schizophrenia, mania, and disturbed behaviour, and of severe anxiety. Like reserpine and tetrabenazine, oxypertine depletes catecholamines, though not serotonin, possibly underlying its neuroleptic efficacy. The molecular structure is strongly similar to solypertine and milipertine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Adrenergic receptor alpha-1 169 Target ID: CHEMBL1907610 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084	Antagonist 2778	54.0 nM [IC50]
Dopamine receptor 60 Target ID: CHEMBL2093868 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084	Antagonist 2778	210.0 nM [IC50]
Adenylate cyclase 13 Target ID: CHEMBL2095179 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084	Inhibitor 8297
Serotonin receptors 2 Target ID: Serotonin receptors Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084	Antagonist 2778	25.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Tardive dyskinesia 15 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6140973	Primary	Preclinical	Unknown Approved Use Unknown
Schizophrenia 298 Sources: http://en.pharmacodia.com/web/drug/1_10056.html	Primary	Approved 8429	FORIT Approved Use Oxypertine is primarily indicated in conditions like Mania, Psychosis, Schizophrenia.
Psychosis 16 Sources: http://en.pharmacodia.com/web/drug/1_10056.html	Primary	Approved 8429	FORIT Approved Use Oxypertine is primarily indicated in conditions like Mania, Psychosis, Schizophrenia.

PubMed

Title	Date	PubMed
Effects of sulpiride and oxypertine on the dopaminergic system in the rat striatum.	1992	1351265
Enhanced separation of filamentous fungi by ultrasonic field: possible usage in repeated batch processes.	2002 Aug 7	12067525
Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry.	2003 Dec 25	14643514
GAF film dosimetry of a tandem positioned beta-emitting intravascular brachytherapy source train.	2003 Jun	12852522

Patents

Sample Use Guides

In Vivo Use Guide

Oxypertine 20 mg given orally as a nocturnal sedative and again on the morning of operation produced relief of anxiety

Route of Administration: Oral

In Vitro Use Guide

Oxypertine inhibited [3H]WB-4101 binding in rat cerebral cortex membranes with IC50 54 nM

Name

Type

Language

OXYPERTINE HYDROCHLORIDE

Common Name

English

NSC-169107

Code

English

1H-INDOLE, 5,6-DIMETHOXY-2-METHYL-3-(2-(4-PHENYL-1-PIPERAZINYL)ETHYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

Oxypertine hydrochloride [WHO-DD]

Common Name

English

OXYPERTINE MONOHYDROCHLORIDE

Common Name

English

Code System Code Type Description

CAS

17506-66-0